☆ 4.6 Article

CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2-Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis

CANCERS (2023)

Rate this paper

The primary rating indicates the level of overall quality for the paper. Secondary ratings independently reflect strengths or weaknesses of the paper.

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2-Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis

Rate this paper

Discover Peeref hubs

Ask a Question. Answer a Question.

Export Citation

Share Paper